newsfilter
← Latest News
GlobeNewswire·

KemPharm Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical Development Strategy

KemPharm to Advance KP1077 for Idiopathic Hypersomnia as Lead SDX Product Candidate Strong Balance Sheet with Cash and Cash Equivalents of $127.8M as of December 31, 2021; Available Cash and Revenues Extend Cash Runway through 2025 and Beyond A